Patents by Inventor Shinobu Shimizu

Shinobu Shimizu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220387507
    Abstract: The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.
    Type: Application
    Filed: October 30, 2020
    Publication date: December 8, 2022
    Applicants: Life Science Institute, Inc., National University Corporation Tokai National Higher Education and Research System, THE JIKEI UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Tokunori YAMAMOTO, Shinobu SHIMIZU, Akira FURUTA, Mari DEZAWA, Yasumasa KURODA
  • Publication number: 20220370510
    Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.
    Type: Application
    Filed: July 29, 2022
    Publication date: November 24, 2022
    Applicants: National University Corporation Nagoya University, TOHOKU UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Life Science Institute, Inc.
    Inventors: Yoshiaki SATO, Yuma KITASE, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA, Masahiro TSUJI
  • Publication number: 20200197446
    Abstract: The purpose of the present invention is to provide a novel medical application of pluripotent stem cells (muse cells) in regeneration medicine. The present invention provides a cell preparation and a pharmaceutical composition which are for amelioration and treatment of brain disorders resulting from fetal growth retardation, such as abnormal motor quality or abnormal neurological development, and which contain SSEA-3 positive pluripotent stem cells isolated from a mesenchymal tissue from a live body or cultured mesenchymal cells. It is assumed that this cell preparation is based on a mechanism where muse cells that are administered to objects having the disorders are engrafted on an impaired brain tissue, thereby ameliorating or treating the disorders.
    Type: Application
    Filed: June 20, 2018
    Publication date: June 25, 2020
    Applicants: National University Corporation Nagoya University, TOHOKU UNIVERSITY, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Life Science Institute, Inc.
    Inventors: Yoshiaki SATO, Yuma KITASE, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA, Masahiro TSUJI
  • Publication number: 20190290702
    Abstract: The present invention addresses the problem of providing a novel use of pluripotent stem cells (Muse cells) for medical purposes in regenerative medicine. The present invention provides a cell preparation and a pharmaceutical composition both for ameliorating and treating perinatal brain damage including learning disability and motor disability, each of the cell preparation and the pharmaceutical composition containing SSEA-3-positive pluripotent stem cells isolated from a mesenchymal tissue collected from a living body or cultured mesenchymal cells. The cell preparation according to the present invention relies on a mechanism that Muse cells are administered to a subject having the above-mentioned damage to cause the engraftment of the Muse cells in a damaged brain tissue, thereby ameliorating and treating the damage.
    Type: Application
    Filed: May 16, 2017
    Publication date: September 26, 2019
    Applicants: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY, LIFE SCIENCE INSTITUTE, INC.
    Inventors: Yoshiaki Sato, Toshihiko Suzuki, Shinobu Shimizu, Masaaki Mizuno, Masahiro Hayakawa, Mari Dezawa
  • Publication number: 20190240262
    Abstract: The purpose of the present invention is to provide a novel medical use of pluripotent stem cells (Muse cells) in the regenerative medicine area. Provided are a cell preparation and a medicinal composition for ameliorating and treating chronic lung disease in newborns, said cell preparation and medicinal composition comprising SSEA-3-positive pluripotent stem cells isolated from a mesenchymal tissue in a living body or cultured mesenchymal cells. The cell preparation according to the present invention is based on a mechanism whereby the aforesaid disease is ameliorated and treated by administering Muse cells to a subject suffering from the disease and engrafting the cells in lung tissues.
    Type: Application
    Filed: August 3, 2017
    Publication date: August 8, 2019
    Applicants: National University Corporation Nagoya University, Life Science Institute, Inc., TOHOKU UNIVERSITY
    Inventors: Yoshiaki SATO, Toshihiko SUZUKI, Shinobu SHIMIZU, Masaaki MIZUNO, Masahiro HAYAKAWA, Mari DEZAWA